MDRNA : Phase 2 Trial of PYY(3-36) Does not Meet Weight Loss Endpoint

July 31, 2008-MDRNA, Inc. (Nasdaq: MRNA) announced results from a Phase 2 clinical trial evaluating PYY(3-36) Nasal Spray (PYY) for the treatment of obesity. The data indicate that PYY did not meet the primary efficacy endpoint of a dose response of weight loss vs. PYY dose, nor did PYY meet the secondary efficacy endpoint of greater weight loss than the active control, sibutramine (Meridia(R))... MDRNA's Press Release -